NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31

NewcelX Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026

$2.63+0.13 (+5.20%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 1.2
Dividend yield: –

NewcelX Ltd. income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Research & Development	1.13	0.99	1.61	8.98	5.92	0.10	0.90	0.71
General & Administrative	1.35	0.81	1.33	6.51	5.94	2.20	3.30	2.74
Operating Expenses	–	4.38	12	15	12	2.30	4.20	3.45
Operating Income	-2.56	-2.07	-3.02	-15	-12	-2.30	-4.20	-3.45
Interest Expense	–	0.05	0.12	0.10	0.05	0.09	0.00	–
Other Non-Operating Income	-5.74	-5.13	-0.32	-1.01	-0.02	-0.33	-0.07	0.02
Gain (Loss) on Sale of Assets	–	–	0.03	–	–	–	–	–
Pretax Income	–	-7.20	-3.28	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	-16	-12	-2.86	-5.45	-5.15
Net Income	-8.30	-7.20	-3.33	-16	-12	-2.86	-5.45	-5.15
Preferred Dividends	–	2.08	–	–	–	–	–	–
Net Income to Common	8.30	7.20	3.33	-16	–	–	–	–
EPS (Basic)(per share)	2.16	2.43	1.13	-33.52	-40.00	-16.40	–	–
EPS (Diluted)(per share)	2.16	2.43	1.13	-33.52	-40.00	-16.40	–	–
Shares Outstanding (Basic, Weighted)(shares)	3.84	2.96	2.96	0.49	0.30	0.17	0.17	0.16
Shares Outstanding (Diluted, Weighted)(shares)	3.84	2.96	2.96	0.49	0.30	0.17	0.17	0.16
EBITDA	-2.51	-1.65	-2.40	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 2225.2%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: 1.2
Price to sales: –
Price to book: –
Dividend yield: –